Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 642041, 11 pages
http://dx.doi.org/10.1155/2015/642041
Research Article

Potential Therapeutic Benefit of Combining Gefitinib and Tamoxifen for Treating Advanced Lung Adenocarcinoma

1Sex Hormone Research Center, Graduate Institute of Clinical Medical Science, School of Medicine, China Medical University, 6 Xueshi Rd., North District, Taichung 40403, Taiwan
2Department of Chest Medicine, Taichung Tzuchi Hospital, The Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan
3Department of Pathology, Taichung Tzuchi Hospital, The Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan
4Center of Molecular Medicine, China Medical University Hospital, Taichung, Taiwan
5Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei, Taiwan

Received 29 August 2014; Revised 25 December 2014; Accepted 25 December 2014

Academic Editor: Noriyoshi Sawabata

Copyright © 2015 Chien-Ming Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Siegel, C. Desantis, K. Virgo et al., “Cancer treatment and survivorship statistics, 2012,” CA: Cancer Journal for Clinicians, vol. 62, no. 4, pp. 220–241, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. C. S. Baik and K. D. Eaton, “Estrogen signaling in lung cancer: an opportunity for novel therapy,” Cancers, vol. 4, no. 4, pp. 969–988, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Shim, G. Pacheco-Rodriguez, J. Kato, T. N. Darling, M. Vaughan, and J. Moss, “Sex-specific lung diseases: effect of oestrogen on cultured cells and in animal models,” European Respiratory Review, vol. 22, no. 129, pp. 302–311, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. J.-S. Seo, Y. S. Ju, W.-C. Lee et al., “The transcriptional landscape and mutational profile of lung adenocarcinoma,” Genome Research, vol. 22, no. 11, pp. 2109–2119, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. T. S. Mok, Y.-L. Wu, S. Thongprasert et al., “Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma,” The New England Journal of Medicine, vol. 361, no. 10, pp. 947–957, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Fukuoka, Y.-L. Wu, S. Thongprasert et al., “Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS),” Journal of Clinical Oncology, vol. 29, no. 21, pp. 2866–2874, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. S.-F. Huang, H.-P. Liu, L.-H. Li et al., “High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan,” Clinical Cancer Research, vol. 10, no. 24, pp. 8195–8203, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. S.-W. Han, T.-Y. Kim, P. G. Hwang et al., “Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib,” Journal of Clinical Oncology, vol. 23, no. 11, pp. 2493–2501, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Mendelsohn and J. Baselga, “Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer,” Journal of Clinical Oncology, vol. 21, no. 14, pp. 2787–2799, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Rosell, T. Moran, C. Queralt et al., “Screening for epidermal growth factor receptor mutations in lung cancer,” The New England Journal of Medicine, vol. 361, no. 10, pp. 958–967, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. K.-P. Chung, Y.-T. Huang, Y.-L. Chang et al., “Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment,” Chest, vol. 141, no. 2, pp. 420–428, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. J.-J. Yang, H. J. Chen, H. H. Yan et al., “Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer,” Lung Cancer, vol. 79, no. 1, pp. 33–39, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. C.-T. Wu, Y.-L. Chang, J.-Y. Shih, and Y.-C. Lee, “The significance of estrogen receptor β in 301 surgically treated non-small cell lung cancers,” The Journal of Thoracic and Cardiovascular Surgery, vol. 130, no. 4, pp. 979–986, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. E. R. Schuur and R. J. Weigel, “Monoalellic amplification of estrogen receptor-α expression breast cancer,” Cancer Research, vol. 60, no. 10, pp. 2598–2601, 2000. View at Google Scholar · View at Scopus
  15. Q. Ye, L. W. K. Chung, B. Cinar, S. Li, and H. E. Zhau, “Identification and characterization of estrogen receptor variants in prostate cancer cell lines,” Journal of Steroid Biochemistry and Molecular Biology, vol. 75, no. 1, pp. 21–31, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. Y.-C. Hung, W.-C. Chang, L.-M. Chen et al., “Non-genomic estrogen/estrogen receptor α promotes cellular malignancy of immature ovarian teratoma in vitro,” Journal of Cellular Physiology, vol. 229, no. 6, pp. 752–761, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. S. H. Yeh and P. J. Chen, “Gender disparity of hepatocellular carcinoma: the roles of sex hormones,” Oncology, vol. 78, supplement 1, pp. 172–179, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. W.-L. Ma, H.-C. Lai, S. Yeh, X. Cai, and C. Chang, “Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis,” Endocrine Related Cancer, vol. 21, no. 3, pp. R165–R182, 2014. View at Publisher · View at Google Scholar
  19. N. Nose, K. Sugio, T. Oyama et al., “Association between estrogen receptor-β expression and epidermal growth factor receptor mutation in the postoperative prognosis of Adenocarcinoma of the lung,” Journal of Clinical Oncology, vol. 27, no. 3, pp. 411–417, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Rades, C. Setter, O. Dahl, S. E. Schild, and F. Noack, “The prognostic impact of tumor cell expression of estrogen receptor-α, progesterone receptor, and androgen receptor in patients irradiated for nonsmall cell lung cancer,” Cancer, vol. 118, no. 1, pp. 157–163, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Kawai, A. Ishii, K. Washiya et al., “Combined overexpression of EGFR and estrogen receptor α correlates with a poor outcome in lung cancer,” Anticancer Research, vol. 25, no. 6, pp. 4693–4698, 2005. View at Google Scholar · View at Scopus
  22. D. Gallo, I. de Stefano, M. G. Prisco, G. Scambia, and G. Ferrandina, “Estrogen receptor beta in cancer: an attractive target for therapy,” Current Pharmaceutical Design, vol. 18, no. 19, pp. 2734–2757, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Navaratnam, G. Skliris, G. Qing et al., “Differential role of estrogen receptor beta in early versus metastatic non-small cell lung cancer,” Hormones and Cancer, vol. 3, no. 3, pp. 93–100, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. J. M. Siegfried, P. A. Hershberger, and L. P. Stabile, “Estrogen receptor signaling in lung cancer,” Seminars in Oncology, vol. 36, no. 6, pp. 524–531, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Omoto, Y. Kobayashi, K. Nishida et al., “Expression, function, and clinical implications of the estrogen receptor β in human lung cancers,” Biochemical and Biophysical Research Communications, vol. 285, no. 2, pp. 340–347, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. C.-K. Toh, B. Ahmad, R. Soong et al., “Correlation between epidermal growth factor receptor mutations and expression of female hormone receptors in East-Asian Lung adenocarcinomas,” Journal of Thoracic Oncology, vol. 5, no. 1, pp. 17–22, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. I. Rouquette, V. Lauwers-Cances, C. Allera et al., “Characteristics of lung cancer in women: importance of hormonal and growth factors,” Lung Cancer, vol. 76, no. 3, pp. 280–285, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. V. Monica, M. Longo, B. Felice, G. V. Scagliotti, M. Papotti, and S. Novello, “Role of hormone receptor expression in patients with advanced-stage lung cancer treated with chemotherapy,” Clinical Lung Cancer, vol. 13, no. 6, pp. 416–423, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. L. P. Stabile, J. S. Lyker, C. T. Gubish, W. Zhang, J. R. Grandis, and J. M. Siegfried, “Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects,” Cancer Research, vol. 65, no. 4, pp. 1459–1470, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Kato, H. Endoh, Y. Masuhiro et al., “Activation of the estrogen receptor through phosphorylation by mitoqen-activated protein kinase,” Science, vol. 270, no. 5241, pp. 1491–1494, 1995. View at Publisher · View at Google Scholar · View at Scopus
  31. P. A. Hershberger, L. P. Stabile, B. Kanterewicz et al., “Estrogen receptor beta (ERβ) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 116, no. 1-2, pp. 102–109, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. P. -L. Yao, F. J. Gonzalez, and J. M. Peters, “Targeting estrogen receptor-beta for the prevention of nonmelanoma skin cancer,” Cancer Prevention Research, vol. 7, no. 2, pp. 182–185, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. W.-M. Chung, W.-C. Chang, L. Chen et al., “MicroRNA-21 promotes the ovarian teratocarcinoma PA1 cell line by sustaining cancer stem/progenitor populations in vitro,” Stem Cell Research & Therapy, vol. 4, no. 4, article 88, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. M. E. Hammond, D. F. Hayes, M. Dowsett et al., “American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer,” Journal of Clinical Oncology, vol. 28, no. 16, pp. 2784–2795, 2010. View at Google Scholar
  35. K. Y. Su, H. Y. Chen, K. C. Li et al., “Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 30, no. 4, pp. 433–440, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Shen, J. Liu, R. Wang et al., “Fulvestrant increases gefitinib sensitivity in non-small cell lung cancer cells by upregulating let-7c expression,” Biomedicine & Pharmacotherapy, vol. 68, no. 3, pp. 307–313, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. R. Xu, H. Shen, R. Guo, J. Sun, W. Gao, and Y. Shu, “Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib,” Biomedicine & Pharmacotherapy, vol. 66, no. 5, pp. 384–389, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Noto, C. de Vitis, G. Roscilli et al., “Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer,” Oncotarget, vol. 4, no. 8, pp. 1253–1265, 2013. View at Google Scholar · View at Scopus
  39. N. Nose, H. Uramoto, T. Iwata, T. Hanagiri, and K. Yasumoto, “Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFR-TKI for adenocarcinoma of the lung,” Lung Cancer, vol. 71, no. 3, pp. 350–355, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Onitsuka, H. Uramoto, and F. Tanaka, “Lack of direct association between EGFR mutations and ER beta expression in lung cancer,” Anticancer Research, vol. 31, no. 3, pp. 855–860, 2011. View at Google Scholar · View at Scopus
  41. A. DeCensi, M. Puntoni, G. Pruneri et al., “Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial,” Cancer Prevention Research, vol. 4, no. 8, pp. 1181–1189, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. P. R. Cammarata, J. Flynn, S. Gottipati et al., “Differential expression and comparative subcellular localization of estrogen receptor beta isoforms in virally transformed and normal cultured human lens epithelial cells,” Experimental Eye Research, vol. 81, no. 2, pp. 165–175, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. B. Manavathi, F. Acconcia, S. K. Rayala, and R. Kumar, “An inherent role of microtubule network in the action of nuclear receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 43, pp. 15981–15986, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. Z. Zhou, J. Zhou, and Y. Du, “Estrogen receptor beta interacts and colocalizes with HADHB in mitochondria,” Biochemical and Biophysical Research Communications, vol. 427, no. 2, pp. 305–308, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Razandi, A. Pedram, V. C. Jordan, S. Fuqua, and E. R. Levin, “Tamoxifen regulates cell fate through mitochondrial estrogen receptor beta in breast cancer,” Oncogene, vol. 32, no. 27, pp. 3274–3285, 2013. View at Publisher · View at Google Scholar · View at Scopus